Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to Chemoradiotherapy of advanced esophageal Squamous cell carcinoma

Digestive Surgery

Volumn 30, Issue 3, 2013, Pages 240-248

  Imanishi, Shunsuke ^a   Shuto, Kiyohiko ^a   Aoyagi, Tomoyoshi ^a   Kono, Tsuguaki ^a   Saito, Hiroshige ^a   Matsubara, Hisahiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Apparent diffusion coefficient; Chemoradiotherapy; Diffusion weighted image; Early response; Esophageal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; AGED; ARTICLE; CANCER STAGING; DIFFUSION WEIGHTED IMAGING; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; HUMAN; MALE; PATHOLOGY; PREDICTIVE VALUE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR INVASION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DIFFUSION MAGNETIC RESONANCE IMAGING; DOSE FRACTIONATION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84883189638     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000351435     Document Type: Article

References (27)

1. Urschel J, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 185: 538-543
2. Patterson DM, Padhani AR, Collins DJ: Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008; 5: 220- 233
3. Lambregts DMJ, Vandecaveye V, Barbaro B, Bakers FCH, Lambrecht M, Maas M, et al: Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 2011; 18: 2224-2231
4. Aoyagi T, Shuto K, Okazumi S, Shimada H, Nabeya Y, Kazama T, Matsubara H: Evaluation of the clinical staging of esophageal cancer by using diffusion-weighted imaging. Exp Ther Med 2010; 1: 847-852
5. Aoyagi T, Shuto K, Okazumi S, Miyauchi H, Kazama T, Matsubara H: Evaluation of ulcerative colitis using diffusion-weighted imaging. Hepatogastroenterology 2010; 57: 468- 471
6. Aoyagi T, Shuto K, Okazumi S, Shimada H, Kazama T, Matsubara H: Apparent diffusion coefficient values measured by diffusionweighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. Dig Surg 2011; 28: 252-257
7. Aoyagi T, Shuto K, Okazumi S, Hayano K, Satoh A, Saitoh H, Shimada H, Nabeya Y, Kazama T, Matsubara H: Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis. Eur Radiol 2012; 22: 1172-1177
8. Hayano K, Miura F, Amano H, Toyota N, Wada K, Kato K, Sano K, Takeshita K, Aoyagi T, Shuto K, Matsubara H, Asano T, Takada T: Correlation of apparent diffusion coefficient measured by diffusion-weighted MRI and clinicopathologic features in pancreatic cancer patients. J Hepatobiliary Pancreat Science 2013; 20: 243-248
9. Park SH, Moon WK, Cho N, Song IC, Chang JM, Park IA, Han W, Noh DY: Diffusionweighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257: 56-63
10. Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T: Neoadjuvant chemotherapy in breast cancer-response evaluation of response to treatment using dynamic contrast- enhanced and diffusion-weighted MR imaging. Eur Radiol 2011; 21: 1188-1199
11. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ: Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003; 2: 581-587
12. Cui Y, Zhang XP, Sun YS, Tang L, Shen L: Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900
13. Song I, Kim CK, Park BK, Park W: Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 2010; 194:W477-W482
14. Zhou R, Yu T, Feng C, Ma L, Wang Y, Li W, Wang Y: Diffusion-weighted imaging for assessment of lung cancer response to chemotherapy. Zhongguo Fei Ai Za Zhi 2011; 14: 256-260
15. Sun YS, Zhang XP, Tang L, Ji JF, Gu J, Cai Y, Zhang XY: Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion- weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010; 254: 170-178
16. Kim S, Loevner L, Quon H, Sherman E, Weinstein G, Kilger A, Poptani H: Diffusionweighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinoma of the head and neck. Clin Cancer Res 2009; 15: 986-994
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
18. Picus D, Balfe DM, Koehler RE, Roper CL, Owen JW: Computed tomography in the staging of esophageal carcinoma. Radiology 1983; 146: 433-438
19. Urschel JD, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 185: 538-543
20. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxi A, Camma C: Preoperative chemoradiotherapy for oesophagealcancer: a systematic review and meta-analysis. Gut 2004; 53: 925-930
21. Malthaner RA, Wong RKS, Rumble RB, Zuraw L: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35
22. Greer SE, Goodney PP, Sutton JE, Birkmey - er JD: Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005; 137: 172-177
23. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis Lancet Oncol 2011; 12: 681-692
24. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907) Ann Surg Oncol 2012; 19: 68-74
25. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516) Jpn J Clin Oncol 2004; 34: 615-619
26. Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J: The value of 18 F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 171-179
27. Lambregts DM, Beets GL, Maas M, Curvo- Semedo L, Kessels AG, Thywissen T, Beets- Tan RG: Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol 2011; 21: 2567-2574.